Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma
PHASE2CompletedINTERVENTIONAL
Timeline
Start Date
July 31, 2003
Primary Completion Date
August 31, 2004
Conditions
Intraocular MelanomaMelanoma (Skin)
Interventions
DRUG
lomustine
DRUG
temozolomide
DRUG
thalidomide
Trial Locations (1)
10021
Memorial Sloan-Kettering Cancer Center, New York
All Listed Sponsors
collaborator
National Cancer Institute (NCI)
NIH
lead
Memorial Sloan Kettering Cancer Center
OTHER
NCT00072345 - Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma | Biotech Hunter | Biotech Hunter